Abbott continues to transform diabetes care with its leading Libre systems and the new FreeStyle Libre 3 Plus* sensor MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that ...

Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus* sensor, is now available to Canadians living with diabetes ...

The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim ...

The FreeStyle Libre 3 (FSL3) is a real-time continuous glucose monitoring (CGM) system designed to replace SMBG. The evidence for the benefit of CGM in people with T2DM on non-intensive insulin ...

Abbott's FreeStyle Libre 3 Plus sensor will be compatible with the twiist AID System, which is expected to launch in Q2 2025. "We are thrilled to announce our collaboration with Abbott, integrating ...

The US Food and Drug Administration (FDA) has cleared the Abbott Libre 2 and 3 continuous glucose monitoring (CGM) sensors for use during most imaging procedures, including MRI under certain ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for incorrect high glucose readings.

The two companies teamed up to collaborate on a continuous glucose monitoring system that combines Abbott’s FreeStyle Libre technology with Medtronic’s automated insulin delivery system.

Abbott has initiated a voluntary medical device correction affecting a limited number of FreeStyle Libre® 3 sensors in the United States, specifically targeting products distributed in the first half ...